Brookfield Asset Management Inc. Zymeworks Inc. Transaction History

Brookfield Asset Management Inc.

  • $14 Billion
  • Q3 2024

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 14, 2022
BUY
$4.65 - $7.43 $238,163 - $380,549
51,218 Added 33.6%
203,652 $1.25 Million
Q2 2022

Nov 16, 2022
SELL
$4.82 - $7.7 $246,870 - $394,378
-51,218 Reduced 25.15%
152,434 $808,000
Q2 2022

Aug 15, 2022
BUY
$4.82 - $7.7 $121,965 - $194,840
25,304 Added 19.9%
152,434 $807,000
Q1 2022

May 16, 2022
BUY
$6.0 - $16.98 $762,780 - $2.16 Million
127,130 New
127,130 $832,000

Others Institutions Holding ZYME

# of Institutions
1
Shares Held
296K
Call Options Held
0
Put Options Held
0
View Full List

About Zymeworks Inc.

ZYME Quotes by TradingView
  • Ticker ZYME
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 61,694,400
  • Market Cap $905M
  • Description
  • Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas...
More about ZYME
Track This Portfolio

Track Brookfield Asset Management Inc. Portfolio

Follow Brookfield Asset Management Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Brookfield Asset Management Inc., based on Form 13F filings with the SEC.

News

Stay updated on Brookfield Asset Management Inc. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email